Going viral: Examining advancements in oncolytic viral therapies and their future

November 17 from 10-11:30 a.m. ET

Oncolytic (cancer-killing) viruses are one of the most promising forms of immunotherapy today because they can effectively target and destroy cancer cells while leaving healthy cells unaffected. By harnessing the unique properties of these viruses, research groups and biotech companies are changing the landscape of cancer therapy. Oncolytic viruses have now moved into the realm of true immunomodulators that can be used as a cancer vaccine platform or to deliver encoded immunomodulatory genes locally in tumours.

On November 17, join the Ontario Institute for Cancer Research and JLABS as we delve into the field of oncolytic virus therapy to understand its emergence, where things stand today and how this precise and promising treatment is being brought to patients. At the symposium you will hear from our keynote speaker Dr. Robert Coffin, a world-leading researcher and Founder, President and Chief Research and Development Officer of Replimune. The session will also feature a presentation from Dr. Carolina Ilkow, Ottawa Hospital Research Institute, on her group’s work studying oncolytic viruses and will conclude with an engaging panel discussion with the speakers and other experts in the field. Come join us and learn about this exciting area and how it may have an impact on your research!